Mona Alfaraj: Therapeutic Apheresis Case Series in Sickle Cell Disease with Fat Embolism Syndrome
Mona Alfaraj, Consultant Hematopathologist and Transfusionist, shared on LinkedIn about a recent article she and her colleagues co-authored, published in Hemoglobin:
“Happy to share that one of our works on therapeutic apheresis has been published. Grateful for the collaboration and the opportunity to contribute in a scientific work that supports better patient care. Proud of the team and the journey behind this work.
For those with trasfusion and apheresis interest, it is worth to emphasize that although plasma is the standard replacement fluid in TPE for FES, a 50:50 replacement protocol using FFP and 5% human albumin was used in both reported cases. This approach aligns with ASFA guidelines , which recommend limiting full FFP replacement to conditions with clear coagulopathy or high bleeding risk.
In sickle cell disease, this mixed replacement strategy aims to reduce donor plasma exposure while ensuring that the FFP provided is sufficient to address any preexisting or exchange-induced coagulopathy.
A similar protocol has been used in other studies involving critically ill patients with sickle cell disease and multi organ failure.
This case series is a step of greater project of optimum utilization of plasma in therapeutic plasma exchange .”
Title: Therapeutic Plasma Exchange as a Rescue Therapy in Sickle Cell Disease-Associated Fat Embolism Syndrome: Case Series and Literature Review
Authors: Abdulmohsen K. Aljishia, Fatimah A. Alrabia, Abdullah M. Al Abbas, Mona M. Alfaraji, Fadhel A. Alomard, Salah Abohelaikac
Read the Full Article on Hemoglobin
Explore more posts for deeper insights into hemostasis with Hemostasis Today.
-
Mar 16, 2026, 19:16Maha Othman: Delighted to See Our Article Receive The Eberhard F. Mammen Most Popular Article Award 2026
-
Mar 16, 2026, 19:03Limited Evidence for Anticoagulation Despite High VTE Risk in Sickle Cell Disease – RPTH
-
Mar 16, 2026, 18:59Bartosz Hudzik: Choosing The Right Anticoagulant for Acute Venous Thromboembolism
-
Mar 16, 2026, 18:54Michael Recht Appointed Chief Medical and Scientific Advisor to NBDF’s Pathway to Cures
-
Mar 16, 2026, 18:46David McIntosh: Moving Beyond Doubts and Ensuring the Safety of Plasma Donation
-
Mar 16, 2026, 18:42Ramy Abdelnaby: Exploring Advances in Antithrombotic Therapy for Noncardioembolic Ischemic Stroke
-
Mar 16, 2026, 18:27Christina (Tina) P: Help Advance Research and Support Patients with Antiphospholipid Syndrome
-
Mar 16, 2026, 18:20Ahmed Koriesh: Stroke Prevention in the New 2026 ACC/AHA Dyslipidemia Guideline
-
Mar 16, 2026, 18:13Nameer Ascandar: Outcomes After GI Bleeding in Patients with Rheumatoid Arthritis and AF on Long-Term Oral Anticoagulation